Nebraska Medicine Hematology/Oncology

www.nebraskamed.com

 

CLL Therapy in 2020 - Ibrutinib+ Rituximab Provides Superior PFS and OS, Fixed Duration Venetoclax/Obinutuzumab, Acalabrutinib Safe and Effective

322 views
March 9, 2020
Comments 0
Login to view comments. Click here to Login